Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata

Olumniant (Barcitinib) has gained swift approval by the Food and Drug Administration (FDA) as a promising medication for the treatment of adults with severe Alopecia Areata. This drug has proven to be effective for various conditions including Covid-19 and Rheumatoid Arthritis as well as being found...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Eman, Owais, Rabia, Sheikh, Ayesha, Shaikh, Asim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422172/
https://www.ncbi.nlm.nih.gov/pubmed/36045780
http://dx.doi.org/10.1016/j.amsu.2022.104157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422172/
https://www.ncbi.nlm.nih.gov/pubmed/36045780
http://dx.doi.org/10.1016/j.amsu.2022.104157

Ejemplares similares